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SUMMARY 
Rabbits are becoming more popular as pet animals and surgical procedures are likewise getting more 
common. Hence the need for postoperative analgesic treatment in the home is increasing. 
Buprenorphine is a partial µ-opioid receptor agonist with long duration and is the therefore useful as a 
postoperative analgesic agent. It is also the most commonly used opioid in rabbits. Buprenorphine has 
poor bioavailability after oral dosing, therefore oral transmucosal (OTM) administration could be an 
option for pet owners. The aim of this study was to compare OTM with subcutaneous (SC) 
administration of buprenorphine by buprenorphine plasma concentrations and facial pain expression 
scoring. 
Eighteen female New Zealand White rabbits with the mean (SD) body weight 3.90 (0.49) kg were 
used in a study on bone replacement, in which a full diaphysis bone segment of 20 mm was removed 
from the radius and replaced by either a monetite implant or autologous bone. Buprenorphine was 
administered postoperatively either SC (0.05 mg/kg) or OTM (0.15 mg/kg) every eighth hour. Blood 
samples were collected before and at 8 time points (15-540 min) after the first administration of 
buprenorphine. Plasma was analysed for concentrations of buprenorphine with ultra-high performance 
liquid chromatography – tandem mass spectrometry. Photographs were taken of the rabbits’ faces 
prior to surgery and postoperatively before each blood sampling. The pictures were scored in a blinded 
fashion for pain assessment both subjectively and with the Rabbit Grimace Scale (RbtGs). 
The OTM administration required large volumes and was difficult to accomplish. Buprenorphine 
plasma concentrations varied largely, especially after SC administration. The maximal plasma 
concentration (Cmax) and the area under the plasma concentration time curve (AUC) were 
significantly lower after OTM than after SC administration (p < 0.05). The median Cmax values were 
0.74 ng/ml and 1.16 ng/ml, and the median AUC values were 41 ng·h/ml and 337 ng·h/ml, for OTM 
and SC administration respectively. Subjective pain and RbtGs scores were well correlated (OTM: ρ = 
0.94 and SC: ρ = 0.90) but did not correlate with buprenorphine plasma concentrations. RbtGs pain 
scores for OTM administration were only significant higher (p < 0.05) at one time point (15 min) out 
of eight compared to SC administration. 
In summary, neither of the administration routes were regarded as reliable as reflected by the large 
variation in plasma concentrations of buprenorphine. Buprenorphine given OTM was not as well 
absorbed as when administered SC given the plasma concentrations. More studies are needed to 
confirm these findings and to find other analgesic treatment alternatives that are owner-friendly.   

SAMMANFATTNING 
Kaniner har blivit populära som husdjur och därmed har även operativa ingrepp ökat. I och med detta 
ökar behovet av smärtlindring på kanin i hemmet. Buprenorfin är en partiell agonist till µ-
opioidreceptorn med lång duration och är därför användbar för postoperativ smärtlindring. Dessutom 
är det den vanligaste opioiden som ges till kanin. Buprenorfin har dålig oral biotillgänglighet därför 
skulle oral transmukosal administrering kunna vara ett alternativ för behandling i hemmet utfört av 
djurägare. Syftet med denna studie var att jämföra två olika administrationsvägar av buprenorfin, 
subkutan och oral transmukosal, genom att mäta plasmahalter av buprenorfin samt utvärdera smärta 
genom att bedöma ansiktsuttryck.  
Arton New Zealand White honkaniner med en medelkroppsvikt (SD) på 3,9 (0,49) kg användes i en 
experimentell studie av nybildning av benvävnad varvid 20 mm av radiusdiafysen avlägsnades och 
ersattes av ett monetitimplantat eller autologt ben. Buprenorfin administrerades postoperativt antingen 
subkutant (0,05 mg/kg) eller oralt transmukosalt (0,15 mg/kg) var åttonde timme. Blodprover togs före 
operation och vid 8 tidpunkter (15-540 min) efter den första buprenorfinadministrationen. 
Plasmahalter av buprenorfin analyserades med ultrahög-prestanda vätskekromatografi - tandem 
masspektrometri. Djurens ansikten fotograferades före operation samt före varje 
blodprovtagningstillfälle. Fotografierna bedömdes blindat för smärta både subjektivt och enligt en 
skala baserad på ansiktsuttryck hos kanin, Rabbit Grimace Scale (RbtGs).  
Oral transmukosal administrering krävde en stor volym och var svår att utföra. 
Plasmakoncentrationerna av buprenorfin varierade kraftigt, särskilt efter subkutan injektion. Den 
maximala plasmakoncentrationen (Cmax) och arean under plasmakoncentrationskurvan (AUC) var 
signifikant lägre efter oral transmukosal jämfört med subkutan administration (p <0,05). 
Medianvärden för Cmax var 0,74 ng/ml för oral transmukosal och 1,16 ng/ml för subkutan 
administrering. Medianvärden för AUC var 41 ng·h/ml för oral transmukosal och 337 ng·h/ml för 
subkutan administrering. 
Smärtpoängen från RbtGs samt subjektiv bedömning var väl korrelerade efter både oral transmukosal 
och subkutan administration (ρ = 0,94 respektive ρ=0,90). Smärtpoängen korrelerade inte med 
plasmakoncentrationer av buprenorfin. Smärtpoängen från RbtGs vid oral transmukosal administrering 
var signifikant högre (p < 0.05) vid endast en tidpunkt (15 minuter) av totalt åtta jämfört med subkutan 
administrering. 
Sammanfattningsvis kan ingen av administrationssätten anses tillförlitliga med ledning av den stora 
variationen i plasmakoncentrationer av buprenorfin. Buprenorfin absorberades inte like väl efter oral 
transmukosal som subkutan administration, givet plasmakoncentrationerna. Fler studier behövs för att 
konfirmera dessa fynd och för att hitta djurägarvänliga alternativ för smärtbehandling i hemmet. 
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INTRODUCTION 
Rabbits are common both in medical research and as pets. In both settings, surgery is sometimes 
necessary, leading to postoperative pain and potential suffering. Despite the increasing knowledge 
about pain processes and the benefits of adequate analgesia, at present rabbits do not always receive 
analgesic treatment after experimental surgical procedures (Coulter et al., 2011). When systemic 
analgesic agents are used in experimental surgery, buprenorphine is the most common agent. 
Because the popularity of rabbits as pets has increased, surgical procedures in pet rabbits have become 
more complex, and with that the need for potent analgesic treatment has increased (as reviewed by 
Barter, 2011). Multimodal analgesia is generally recommended (Weaver et al., 2010; Coulter et al., 
2011) and opioids and NSAIDs can be combined in an analgesic protocol. NSAIDs have the 
advantage that they can be given orally and can therefore be easily administerad by pet owners (as 
reviewed by Barter, 2011). Opioids and other analgesic agents than NSAIDs are usually administered 
parenterally. However, opioids can be administered by the oral transmucosal route (OTM), thereby 
avoiding the first-pass liver effect, as well as making it possible for owners to treat animals at home. 
This route of administration has been evaluated in e.g. cats, but only to a limited extent in rabbits (see 
below).   
One potent opioid for treatment of postoperative pain is buprenorphine, which and can be 
administered by the subcutaneous (SC), intramuscular (IM) or intravenous (IV) route in rabbits 
(Wootton et al., 1988; Shafford & Schadt., 2008; Cooper et al., 2009.) The OTM administration of 
buprenorphine has been proved reliable regarding its analgesic effects and pharmacokinetics in cats 
and dogs (Robertson et al., 2005; Abbo et al., 2008; Giordano et al., 2010), with most studies 
published in cats. There are only few studies published on OTM administration of buprenorphine in 
rabbits (Lindhardt et al., 2001; Yeola et al., 2014), and it seems not to be a commonly practiced 
administration route. 
To treat pain efficiently, pain must be correctly assessed, and pain assessment in rabbits is not 
considered an easy task. It is most probably due to the rabbit’s natural behaviour as a prey species, 
which is believed to have a great impact on behaviour-based pain scoring (as reviewed by Barter, 
2011). Recently, facial expression scoring systems have been established in several animal species 
(Dalla et al., 2014; Oliver et al., 2014; Miller & Leach, 2015), including the rabbit (Keating et al., 
2012). Facial expression scoring is suggested to be both a dependable and precise method to assess 
acute pain in rabbits. 
The aim of this study was to compare OTM with SC administration of buprenorphine for 
postoperative analgesia in rabbits after orthopaedic surgery. For the comparison, buprenorphine 
plasma levels were measured and postoperative pain assessed with the Rabbit Grimace Scale and 
subjective pain scoring. If OTM administration is shown to be a reliable administration route, it could 
be useful for treatment of postoperative pain in pet rabbits by the owners at home.  
 
LITERATURE REVIEW 
Pain Recognition in Rabbits 
Pain recognition is a challenge in rabbits (as reviewed by Barter, 2011). The variation in response to 
pain and lack of objective parameters make assessment very difficult. Pain assessment in rabbits has 
mostly been performed with behaviour-based pain scoring systems, in which pain is indicated by 
changes in gait, posture, locomotion and group dynamics. Good knowledge of normal rabbit behaviour 
is important and at best the individual behaviour of the rabbit is known to the observer. The most 
common pain-related behaviour in rabbits is however inactivity (Leach et al., 2009). Moreover, 
behaviour-based scoring systems have not been very successful due to the observer’s impact on the 
rabbit (causing stress).  
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In 2010 Leach et al investigated people’s ability to assess pain in rabbits. People of both sexes, 
different professions and experiences of rabbits scored pain in spayed rabbits from 1-minute long 
video episodes, using a visual analogue pain scale. With the help of eye tracking equipment, they 
showed that most people focus on the face of the rabbits. The authors claimed that this resulted in less 
accurate pain assessment because pain-related behaviour was seen on the abdomen, ears, back and 
hindquarters. Focusing on the whole animals was their recommendation. 
However, face-focusing pain assessment scoring methods have been developed on different animal 
species after that. Although more research is needed, the grimace scales show promising results for 
pain assessment in horses (Dalla et al, 2014), rats (Oliver et al, 2014) and mice (Miller & Leach, 
2015).  
Rabbit Grimace Scale 
The Rabbit Grimace Scale (RbtGs) is a pain assessment scale in which ear position, orbital tightening, 
cheek flattening, nose shape and whisker position are scored from 0-2 (0: not present, 1: moderately 
present, 2: obviously present). Keating et al (2012) evaluated the RbtGs for the capacity of assessing 
acute nociceptive pain. They recorded behaviour changes, heart rate, arterial blood pressure, serum 
cortisone concentration, facial expressions and home pen behaviours in four different groups of rabbits 
which underwent true or sham ear tattooing with or without prior EMLA cream application. Their 
results showed that the RbtGs is a useful tool for pain assessment. Prior EMLA cream treatment 
resulted in a significantly lower pain score at tattooing. 
Pain Management in Rabbits 
Coulter et al. (2011) surveyed 128 published scientific articles on rabbits undergoing experimental 
surgical procedures and compared the reported analgesic administration in 1995-1997 to 2005-2007. 
Unfortunately, not all rabbits received pain relief, however analgesic administration increased 
significantly from the first to the second time period. Buprenorphine was the most commonly used 
agent. Analgesia was mostly administered postoperatively and the authors recommend that analgesic 
treatment is given pre- and intraoperatively as well. They also suggest more frequent use of 
multimodal analgesia, with opioids, NSAIDs and local anaesthesia. 
For analgesia, NSAIDs and opioids are most commonly used (as reviewed by Barter, 2011). Local 
anaesthetics, α2-agonists and NMDA-antagonists can also be used. NSAIDs are suitable for treatment 
of both acute and chronic pain of a mild to moderate degree. Its anti-inflammatory action and 
synergistic action with opioids is favourable when it comes to postoperative pain management.  
Rabbits tolerate NSAIDs well and side effects like renal and hepatic dysfunction and gastric ulcers do 
not seem to occur in rabbits as often as in other animals (as reviewed by Barter, 2011). NSAIDs may 
be given by the oral route and can therefore be administered by the owner. However, in cases of 
moderate to severe pain the effect of NSAIDs may not fully cover the analgesic need.    
Local anaesthetics act on neural transmission of antinociceptive input and lidocaine and bupivacaine 
are commonly used in the veterinary field (as reviewed by Barter, 2011). These can be administered 
topically, injected via infiltration, regional nerve block and epidurally. Many of the 
administration/injection techniques require sedation or general anaesthesia. In some species 
continuous rate infusion of lidocaine is used for analgesia and promoting gastrointestinal motility. The 
use of lidocaine continuous rate infusion (CRI) in rabbits has only been investigated under general 
anaesthesia (as reviewed by Barter, 2011). 
Alpha-2-adrenergic agonists provide sedation, muscle relaxation and analgesia (as reviewed by Barter, 
2011). One big advantage is the possibility to reverse their effect with α2-adrenergic antagonists. 
Alpha-2-agonists have a severe influence on the cardiovascular system by reduction of cardiac output 
and bradycardia making them unsuitable for administration by the pet owner. 
13 
 
Ketamine is an NMDA-receptor antagonist which is frequently used in higher doses for heavy 
sedation or anaesthesia in rabbits (as reviewed by Barter, 2011). The NMDA-receptor plays an 
important role in central sensitization of pain and continuous infusions of sub-anaesthetic doses can be 
used for its analgesic properties and for anaesthetic-sparing purposes. In rodent chronic pain models 
ketamine has been used with success to treat pain (as reviewed by Barter, 2011). 
Buprenorphine  
Opioids’ antinociceptive properties are achieved through their binding to µ- and κ-opioid receptors 
which are distributed throughout the central nervous system (as reviewed by Barter, 2011). 
Buprenorphine is also an agonist of the nociceptin receptor ORL1. This binding inhibits ascending 
nociceptive activity, reduces neurotransmitter release and activates inhibitory conduits. Not only 
obvious parenteral administration routes can be used for opioids but also transdermal, sublingual, oral, 
local and epidural routes. Adverse effects include sedation, respiratory depression and decreased 
gastrointestinal motility. Buprenorphine, which is a partial µ-agonist, has a limited effect and is 
therefore recommended for mild to moderate pain. Sedation is less severe when using buprenorphine 
compared to full µ-agonists (as reviewed by Barter, 2011).  
Buprenorphine has a high affinity and slow association/dissociation at the µ-receptor site but lower 
efficacy compared to full µ-agonists (as reviewed by Barter, 2011). It is a lipophilic molecule and has 
a high volume of distribution. It is predominately metabolised in the liver. For use in humans different 
sublingual and transdermal solutions of buprenorphine have been developed. The main adverse effects 
of buprenorphine are caused by the agonist action on the µ-opioid receptor. Thermal analgesiometric 
tests suggest a duration of slightly shorter than 8-10 hours in rabbits (Wootton et al., 1988) The 
analgesic efficacy is limited; therefore increasing the dose above a certain level does not increase the 
degree of pain relief (as reviewed by Barter, 2011).  
Studies in Rabbits 
Several studies on different postoperative analgesic regimes have been performed in rabbits 
undergoing ovariohysterectomy. Cooper et al. (2009) investigated the analgesic properties of 0.03 
mg/kg buprenorphine administered IM every 12 h for 2 days compared to animals receiving 0.2 mg/kg 
meloxicam subcutaneously SC every 24 h for 2 days, or incisional infiltration with 0.5 ml of 0.5 % 
bupivacaine (body weight 2.0-3.0 kg). Food intake, fecal and urine output and body temperature were 
measured, blood samples and rectal culture examined and clinical examination and auscultation 
performed. They also assessed behaviour and pain based on daily evaluation of appetite, posture, 
grooming and activity. There was no significant difference between the meloxicam and the 
buprenorphine groups. The rabbits which only received local anaesthesia showed significantly lower 
food consumption, fecal production and body weight than in the other two groups. 
Weaver et al. (2010) performed a similar study on rabbits after ovariohysterectomy. Investigating the 
effect of 0.02 mg/kg buprenorphine SC every 12 h for 3 days in comparison with a fentanyl patch (25 
µg) placed 24 hours prior to surgery, a subcutaneous injection of 1 mg/kg ketoprofen every 24 h for 3 
days or no analgesia at all. There were no differences between any of the analgesic treatment groups 
regarding food and water consumption, fecal output, mean travel distance or remotely recorded 
behaviours. Like Coulter et al. (2011) the authors recommend the use of multimodal analgesia and 
consider the lack of research on efficient doses of analgesic agents to rabbits as a major limitation. 
Goldschlager et al. (2013) showed that multimodal analgesia with buprenorphine and meloxicam has a 
reducing effect on the levels of fecal glucocorticoid metabolites (FCM). The dosing regimen used was 
0.03 mg/kg buprenorphine SC q 12 h and 0.02 mg/kg meloxicam SC q 24 h for 3 days. The surgery 
performed was a minimal invasive vascular cut-down. Rabbits in the control group received an 
injection of 2.5 mg bupivacaine (body weight 3 kg) in the incision area. The buprenorphine-
meloxicam group had unchanged levels of FCM until day 3 when the treatment was finished. The 
rabbits in the buprenorphine-meloxicam group gained more weight during 28 days. 
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Transmucosal Administration of Buprenorphine 
Studies in Cats 
Several studies on OTM administration have been performed in cats. In a study by Robertson et al. 
(2005) 0.02 mg/kg buprenorphine was administered IV or OTM in cats. The analgesic effect was 
evaluated by thermal threshold testing (53.6 ±2.1 °C for IV, 51.4 ±4.5 °C for OTM). The plasma 
concentrations were analysed by iodine125-labeled radio-immunoassay. Blood was sampled form the 
jugular vein. Plasma buprenorphine concentration over time AUC measured for both IV and OTM 
showed no significant difference. The peak analgesic effect occurred at 90 minutes and the onset time 
was 30 minutes in both groups. OTM administration of buprenorphine was therefore regarded as 
efficient as IV administration.  
Porters et al. (2015) performed a similar study on the absorption of 0.02 mg/kg buprenorphine and 
0.04 mg/kg dexmedetomidine given by the OTM versus the IM route in cats. The plasma 
concentrations were analysed with liquid chromatography-tandem spectrometry. The results showed 
that the time to reach Cmax was significantly longer after OTM administration and the area under 
concentration-time curve and the maximum plasma concentration were significantly lower. The 
conclusion was that absorption after OTM administration was not as good as when administered IM. 
Giordano et al. (2010) studied the postoperative analgesic effects of 0.01 mg/kg buprenorphine 
administered either IV, IM, SC or OTM in cats who underwent ovariohysterectomy. To estimate pain 
and sedation a Simple Descriptive Scale and a Dynamic and Interactive Visual Analog Scale were 
used. There were no significant differences between any of the groups.  
Porters et al. (2014) performed a study on the sedative and antinociceptive effects of 0.04 mg/kg 
dexmedetomidine and 0.02 mg/kg buprenorphine administered in combination by the OTM or IM 
routes in cats, similar to the study by Giordano et al. (2010). Analgesia to mechanical stimuli (pressure 
rate onset device and ear pinch) and sedation were assessed through an interactive analogue scale. 
Also used to measure pain was mechanical threshold testing. No significant differences were seen in 
either sedation or analgesia between the groups. 
Studies in Dogs 
Abbo et al. (2008) did a pharmacokinetic study on OTM administration of buprenorphine in dogs. 
Two doses were evaluated (0.02 mg/kg and 0.12 mg/kg). Liquid chromatography-electrospray 
ionization-tandem mass spectroscopy was used for analysing the plasma concentrations. 
Bioavailability was higher for the high dose (47 ± 16 % compared to 38 ± 12 %). Cmax for both doses 
were similar. The authors’ conclusion was that OTM administration might be an alternative for pain 
management in dogs. 
In dogs undergoing ovariohysterectomy Ko et al. (2011) studied plasma concentrations (using liquid 
chromatography-electrospray ionization-tandem mass spectroscopy) and postoperative analgesic 
properties (dynamic interactive pain scales) when buprenorphine was administered IV (0.02 mg/kg), 
OTM at a low dose (0.02 mg/kg) or OTM high dose (0.12 mg/kg). The number of dogs in need of 
rescue analgesia and the duration of analgesia did not differ between any of the groups. Buprenorphine 
at a high dose (0.12 mg/kg) given OTM prior anaesthetic induction can be an analgesic alternative was 
the assumption made. 
Studies in Rabbits 
Rabbits have been used in studies on transmucosal administration of buprenorphine to evaluate 
different formulations of buprenorphine but not for the purpose of treating rabbits per se (Lindhardt et 
al., 2001; Yeola et al., 2014). A study that examined transmucosal administration of buprenorphine in 
rabbits, sheep and humans was performed by Lindhardt et al. (2001). Two different types of 
formulations (PEG 300 and dextrose) containing 0.6 mg buprenorphine were given intranasally to 
rabbits with the mean weight 3.9 kg. There was not a significant difference in bioavailability between 
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the two formulations. The mean Cmax value (SD) after intranasal administration was 28 (11) ng/ml 
(PEG 300) and 27 (7) ng/ml (dextrose). Tmax in the study were 8 ± 6 min (PEG 300) and 12 ± 6 min 
(dextrose). 
Summary of Transmucosal Administration Studies 
In summary, the pharmacokinetic studies show different results when comparing OTM to other 
administration routes, whereas no differences in efficacy can be detected when scoring pain and 
sedation. The bioavailability after intranasal administration in rabbits is high. 
 
MATERIAL AND METHODS 
Animals and Housing 
Twenty female New Zealand White Rabbits aged 8-9 months bred by a licensed SPF-breeder 
(Lidköpings kaninfarm, Lidköping, Sweden) were used in a study for evaluation of a new type of 
monetite dental implant. The rabbits were randomised to be housed in either in pairs in floor pens (2 
m2) or singly in cages (0.42 m2) to examine whether housing space has an effect on bone regeneration. 
The rabbits were acclimatized for at least 2 weeks. They were weighed daily for one week prior to 
surgery. Mean body weight (SD) at the time of surgery was 3.90 (0.49) kg. They were fed with 
autoclaved hay and pelleted rabbit diet (Lactamin K1, Lantmännen Lantbruk, Malmö, Sweden). They 
had access to water ad libitum. The local ethics committee for animal research had approved the 
experiment (Dnr C107013/15). 
Anaesthesia and Surgery 
Preparations and Induction of Anaesthesia 
On the day of surgery, the rabbits were clinically examined (estimation of general condition, 
auscultation of heart and lungs). Anaesthesia was induced with 0.25 mg/kg medetomidine (Sedator 
vet, 1 mg/ml, Dechra Veterinary Products, Bladel, Netherlands) and 15 mg/kg ketamine (Ketaminol® 
vet, 100 mg/ml, Intervet, Boxmeer, Netherlands) SC. Once anaesthetized, they received 5 mg/kg 
carprofen (Norocarp vet, 50 mg/ml, N-vet, Newry, Northern Ireland) SC, 10 mg/kg ceftiofur 
(Excenel® vet, 4 g, Orion Pharma Animal Health, Helsinki, Finland) IM and 0.5 mg/kg 
metoclopramide (Primperan®, 5 mg/ml, Sanofi, Stockholm, Sweden) SC. Ceftiofur administration 
was repeated after 90 min if surgery was still ongoing. The fur was clipped on the ears, the base of the 
tail, on one front leg and axilla (randomized side). Ropivacaine (Narop®, 10 mg/ml, AstraZeneca, 
Södertälje, Sweden) was injected SC at a volume of 0.9-1.5 ml at the site of the brachial plexus. One 
IV (22 G BD Venflon™, BD AB, Stockholm, Sweden) and one arterial catheter (20 G BD 
Venflon™, BD AB, Stockholm, Sweden) were placed on opposite ears. The catheters were flushed 
with 2 ml saline and the arterial catheter was filled with 0.14 ml heparin (Heparin LEO, 5000 IE/ml 
LEO Pharma, Malmö, Sweden) diluted with saline to the concentration of 100 IE/ml. The surgical site 
was aseptically prepared. The arterial catheters were used for measuring invasive blood pressure 
intraoperatively and collecting blood samples postoperatively. 
Anaesthesia Maintenance and Monitoring 
During surgery, anaesthesia was maintained with 0.5-1.5 % isoflurane (Attane vet, 1000 mg/g, VM 
Pharma, Northumberland, Great Britain) in oxygen (1.0-3.0 L/min) via a laryngeal mask (V-gel 
supraglottic airway device, size large, Docsinnovent ltd, London, Great Britain). Ringer acetate 
(Ringer-Acetat Baxter Viaflo, Baxter, Kista, Sweden) was administered at a rate of 10 ml/kg/h IV 
during surgery. If mean arterial pressure (MAP), measured in the auricular artery, decreased below 60 
mm Hg, the rate of Ringer acetate was increased to 20 ml/kg/h. If MAP decreased below 50 mm Hg, a 
colloid volume expander (Voluven, Fresenius Kabi, 60 mg/ml, Uppsala, Sweden) was administered at 
a rate of 9 ml/kg/h. If apnea occurred, end tidal CO2 (ETCO2) increased above 7 kPa or oxygen 
16 
 
saturation (SpO2) decreased below 90 %, manual ventilation was performed by squeezing the 
breathing bag. Every 15 minutes respiratory rate, heart rate, blood pressure, SpO2, inspiratory 
concentration of isoflurane, flowrate of O2, colour of mucous membranes and rectal temperature were 
noted. The surgery lasted approximately 1 hour. Total duration of anaesthesia was approximately 1.5-2 
hours. 
Surgery 
A 20 mm long fraction of the radius diaphysis was removed, a so called critical size defect, in the 
sense that conservative healing was impossible. This model is described in a Standard Guide for Pre-
clinical in vivo Evaluation in Critical Size Segmental Bone Defects F2721-09, (ASTM International, 
2014). In place of the defect, ten rabbits received a new type of monetite implant and ten received 
autologous bone as control. The autologous bone consisted of the removed bone which was macerated 
before autotransplantation. 
Postoperative Care 
After termination of surgery and inhalation anaesthesia the animal was extubated and kept in a heated 
chamber (25 °C) and examined every 15 minutes (respiration rate, colour of mucous membranes, 
degree of sedation). If needed, 0.2-0.25 ml atipamezole (Antisedan® vet., 5 mg/ml, Orion Pharma 
Animal Health, Espoo, Finland) was administered IM.  
Study Design 
Pilot Study 
Two weeks before the main study, a pilot study was carried out with two rabbits. One was randomised 
to receive a monetite implant and the other received autologous bone. One was randomised to be 
administered 0.05 mg/kg buprenorphine by the OTM and the other by the SC route. Data from the 
rabbit receiving buprenorphine SC was included in the results from the main study. The rabbit that 
received buprenorphine OTM, did not have detectable plasma concentrations. It was therefore decided 
to administer 0.15 mg/kg OTM in the main study, a dose similar to the one used in the study by 
Lindhardt et al. (2001). Additionally in the pilot study, the duration of the brachial plexus nerve block 
and the time to recovery from anaesthesia was examined to minimize the risk of confounding effects 
of ropivacaine local anaesthesia and sedation on the evaluation of the analgesic effect of 
buprenorphine.   
Buprenorphine Administration 
Rabbits were randomised to receive buprenorphine (Temgesic®, 0.3 mg/ml, RB Pharmaceuticals, 
Slough Berkshire, Great Britain) either SC in the neck area (0.05 mg/kg) or OTM (0.15 mg/kg). 
Buprenorphine was administered 3-4 hours after the brachial plexus nerve block, approximately 2-2.5 
hours after end of inhalation anaesthesia. The OTM administration volume ranged from 1.65-2.5 ml 
and was divided between the two cheeks. The animal was either held by the scruff or wrapped in a 
towel for immobilization and held in a supine position to keep the buprenorphine in the mouth during 
administration.  
Blood Sampling and Analysis 
Blood samples were collected 15, 30, 60, 90, 120, 240, 360 and 540 minutes after administration of 
the first buprenorphine dose. Two ml of blood were collected from the arterial catheter at each time 
point. The catheter was flushed with 2 ml saline and filled with 0.14 ml 100 IE/ml heparin. 
Buprenorphine administration was repeated after 480 min.  
The blood was collected in EDTA-tubes. The tubes were centrifuged and plasma was separated and 
frozen at -80 °C. The analyses were carried out with ultra-high performance liquid chromatography – 
tandem mass spectrometry by the Swedish National Veterinary Institute (SVA, Uppsala, Sweden).  
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Photographs and Pain Scoring 
Three pictures were taken from the front and three from the side of the head before every blood 
sampling with a digital camera (Panasonic Lumix DMC-T27, Osaka, Japan). Two pictures of each 
rabbit at each time point were scored for abnormal ear position and orbital tightening (0; not present, 
1: moderately present, 2: obviously present) according to the Rabbit Grimace Scale (Keating et al, 
2012) by a person blinded to treatment. Nose pointing, whisker position and cheek bulging was not 
scored because no differences were detected for these facial action units. Additionally, photos were 
scored subjectively with a score from 0 (no pain) to 2 (obviously in pain).  
Continuous Care and Medication  
Once blood sampling was completed, buprenorphine was administered SC to all animals for 3 days 
every 8 hours at a dose of 0.03 mg/kg SC. Carprofen was administered daily for 3 days 
postoperatively at a dose of 5 mg/kg sc. Metoclopramide (0.5 mg/kg SC) was repeated twice at 12 
hour intervals. If a rabbit was observed not eating or producing faeces after 12 h, of Ringer acetate 
solution (20-100 ml) was administered SC and approximately15 ml of recovery food for herbivores 
(Critical Care®, Oxbow Animal Health, Murdock, USA) was fed by syringe every 6 hours. 
Statistical Method and Analysis 
For each animal Cmax, Tmax (time to reach Cmax), t1/2 (half-life) and AUC (area under the plasma 
concentration curve) were calculated. AUC was further calculated for RbtGs scores and subjective 
pain scores. Due to the small number of animals and data not being normally distributed, Mann-
Whitney Rank Sum Test was used for comparisons between groups. A-two-way-repeated-measures 
analysis of variance was performed on plasma concentration and RbtGs with group and time as 
factors. Tests were performed in SigmaPlot 11.0 (2008, Systat Software Inc, Hounslow,  
London, UK). A p-value of <0.05 was considered significant. 
RESULTS 
One rabbit died due to peracute haemorrhagic E. coli enteritis prior to the start of the study. One rabbit 
died shortly after intubation following a severe drop in blood pressure and apnoea. Anaesthesia 
maintenance was otherwise uneventful. One rabbit in the pilot study was given too low dose of 
buprenorphine OTM to have measurable plasma concentrations and was therefore excluded. 
Two rabbits were excluded from the study because they had too few blood samples. This due to one 
rabbit removed the arterial catheter when the early blood samples were taken. And the other one 
because it developed neurological signs also early on while blood sampling most likely due to 
complications caused by the arterial catheter. This left seven rabbits in group SC and eight rabbits in 
group OTM for buprenorphine analyses. For one of the rabbits in the SC group several photographs 
for pain scoring were missing. This left six rabbits in the SC group and eight rabbits in the OTM group 
rabbits for the analyses of pain scores. 
Buprenorphine Plasma Concentrations 
Plasma concentrations are shown in figure 1.  
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Fig. 1: Mean (SD) buprenorphine plasma concentrations over time in rabbits after administration of 0.15 mg/kg 
OTM (n=8) or 0.05 mg/kg SC (n=7). Concentrations were measured with ultra-high performance liquid 
chromatography – tandem mass spectrometry. * p<0.05 between groups (two-way analysis of variance). 
 
Cmax and AUC were higher after SC administration. There were no differences between 
administration routes for t1/2 and Tmax (Table 1). 
 OTM administration SC administration 
 
Median  Minimum Maximum  Median  Minimum Maximum 
Cmax (ng/ml) 0,74* 0,15 1,05 1,16* 1,01 8,56 
Tmax (min) 15 15 30 15 15 45 
t1/2 (min) 32 22 139 50 25 231 
AUC (ng*h/ml) 41*  5,69 159 337* 72,6 657 
 
 
 
   Table 1:  Pharmacokinetic results after administration of buprenorphine in rabbits either orally transmucosally 
(OTM, 0.15 mg/kg, n=8) or subcutaneously (SC, 0.05 mg/kg, n=7). Median, maximum and minimum values. *p 
< 0.05 (Mann-Whitney Rank Sum Test). 
 
Pain Assessment 
RbtGs scores were increased in both groups at every time point compared to values before surgery (0), 
except at the last time point in group OTM (Fig 2). The score was higher in the OTM group at 15 min. 
The median AUCs did not differ between groups (RbtGs scores: 1028 for SC (n=6) and 1091 for OTM 
(n=8); subjective pain scores: 735 (n=6) for SC and 540 for OTM (n=8)). RbtGs scores and subjective 
pain scores were well correlated both after OTM and SC administration. (OTM: ρ= 0.94, SC: ρ= 0.9) 
(Fig 3-4). There was no correlation between buprenorphine plasma concentrations and RbtGs scores or 
subjective pain scores. 
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* 
Fig 2: Mean (SD) Rabbit Grimace Scale scores over time in rabbits after administration of 0.15 mg/kg OTM 
(n=8) or 0.05 mg/kg SC (n=6). *p<0.05 (two way analysis of variance) 
 
 
Fig. 3: Correlation between Rabbit Grimace Scale (RbtGs) scores and subjective pain scores in rabbits 
after administration of 0.15 mg/kg buprenorphine orally transmucosally (OTM, n=8). 
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Fig. 4: Correlation between Rabbit Grimace Scale (RbtGs) scores and subjective pain scores in rabbits after 
administration of 0.05 mg/kg buprenorphine subcutaneously (SC, n=6).  
DISCUSSION 
OTM Administration  
In the literature study there is mixed opinions whether OTM administration of buprenorphine is 
regarded as a reliable administration route when studying the pharmacokinetics. Hedges et al. (2014) 
showed that measuring drug concentrations in jugular vein blood following buccal administration may 
give misleading plasma concentrations. This is because the absorbed drug is drained into the jugular 
vein. Both Robertson et al. (2005) and Porters et al. (2015) used jugular vein catheters for collection 
of blood. However, despite equal OTM doses, the results differ regarding the resulting plasma 
concentrations of buprenorphine.  In the study by Porters et al. (2015) the mean Cmax was 0.52 ± 0.32 
ng/ml and in the study by Robertson et al. (2005) the median Cmax (minimum Cmax, maximum 
Cmax) was 12.5 ng/ml (2.55-19.4 ng/ml).  
The analysis methods differed between the two studies. Robertson et al. (2005) used a 
radioimmunoassay and Porters et al. (2015) liquid chromatography-tandem spectrometry. In the 
current study ultra-high performance liquid chromatography – tandem mass spectrometry was the 
analysis method. Porters et al. used a combination of dexmedetomidine and buprenorphine which may 
have influenced the pharmacokinetic analysis. Robertson et al. also assessed pain with thermal 
threshold testing which gave more information than just buprenorphine plasma concentrations to 
conclude that OTM administration is as efficient as IV for analgesia. 
One challenge in the current study was to administer buprenorphine OTM. The immobilisation of the 
rabbit may be difficult for owners and there is the risk of buprenorphine being swallowed or pouring 
out of the mouth because of the large volumes being administered. If swallowed, he drug undergoes 
first pass metabolism by the liver.  
Buprenorphine plasma concentrations  
In the current study, the variation in plasma concentrations of buprenorphine was very large after SC 
administration. This has also been found to be the case in cats, and SC administration was therefore 
discouraged (Steagall et al., 2013). The variation in plasma concentrations in the current study was 
smaller after OTM administration. It cannot be excluded that Cmax occurred before the 15 minute 
time point. The AUC and Cmax were lower after OTM than SC administration, despite the fact that 
the OTM dose was three times higher.  
The poor correlation between buprenorphine plasma concentrations and pain scores shows that plasma 
concentrations cannot be used to monitor analgesia. The reason is that plasma concentrations do not 
reflect the concentrations in the tissues where the opioid receptors are located (Ohtani et al., 1994). 
Since buprenorphine has a slow association/dissociation at the opioid receptor site, the drug can act its 
antinociceptive properties for long time even if its concentration might not be measureable in plasma.  
In the current study the mean (SD) Cmax after OTM administration of 0.15 mg/kg was 0.65 (0.32) 
ng/ml. In the study by Lindhardt et al. (2001) the mean Cmax value after nasal administration of a 
similar buprenorphine dose was 28 (11) ng/ml for the PEG 300 formulation and 27 (7) ng/ml for the 
dextrose formulation. Mean Tmax in the study by Lindhardt et al were 8 min (PEG 300) and 12 min 
(dextrose) whereas it was 21 min in the current study. The difference in Cmax may have been 
influenced by the differences in the starting point of blood sampling; Lindhardt et al. started blood 
sampling earlier, and found that Tmax occurred before 15 min. It can also be that buprenorphine is 
better and faster absorbed from the nasal mucosa (Lindhardt et al., 2001) than the buccal mucosa, 
and/or that PEG increased the rate of absorption, resulting in higher plasma concentrations. The 
buprenorphine solution used in the current study is formulated for injection and contains, apart from 
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buprenorphine hydrochloride, glucose, water and hydrochloric acid. The bioavailability study by 
Lindhardt et al. showed no significant difference between the formulations. 
Pain Scoring 
There was no correlation between plasma concentration levels and RbtGs scores or subjective pain 
scores. Fifteen minutes after administration of buprenorphine a significant higher pain score was found 
after OTM administration compared to SC. Considering the prolonged onset of analgesia found in 
other studies, this is unlikely be due to the action of buprenorphine. During the first 90 min pain scores 
tended to be higher in the OTM group, but the variation is large and from 120 min the pattern was 
reversed. Since the variation in scores was very large, larger groups of rabbits need to be studied to get 
conclusive results about possible differences between routes of administration.  
There are some weaknesses with the study. For instance pain was not scored before administration of 
buprenorphine (baseline pain score). There is thus the possibility that the groups differed in pain 
scores from the start. Further, there was no control group without buprenorphine administration. To 
include such a group was considered unethical, but may have given more conclusive results. Also, 
there was only one person that performed the pain assessment and only two of the RbtGs criteria were 
used. It is possible that the scoring method was too crude to detect small differences in degree of pain. 
It may also be that the rabbits hid their facial expressions because of stress caused by the 
photographer. Perhaps direct evaluation by an observer could have made it possible to assess more 
criteria. Some rabbits were still sedated at the time of scoring, which may have impacted pain and/or 
scoring. This however likely affected rabbits in both groups similarly. 
It would have been valuable to have recorded other pain-associated behaviours like in other studies on 
buprenorphine’s analgesic properties in rabbits (Cooper et al., 2009; Weaver et al., 2010), and to have 
registered physiological findings related to pain as further tools to evaluate pain additionally or in 
comparison to the RbtGs scores. 
Arterial Catheter Use 
Using arterial catheters for continuous blood sampling was a risky event. The benefit was that blood 
collection was easier to perform, and larger quantities could be collected faster compared to collection 
by venepuncture. Three rabbits developed neurological symptoms that may have been related to 
flushing the arterial catheter. The probable cause for the neurological symptoms were emboli of blood 
clots causing ischemia in the brain. This occurred despite of the catheters being flushed with saline 
and filled with heparinised NaCl. Some rabbits also removed the catheters themselves. In one rabbits 
the bleeding was substantial and probably caused the death of the rabbit despite supportive care. 
CONCLUSIONS 
1. OTM administration of buprenorphine was difficult to perform due to large volumes and the 
immobilization of the animal. 
2. OTM administration of buprenorphine give significantly lower plasma concentrations than SC 
administration.  
3. SC administration of buprenorphine leads to a large variation in plasma concentrations which 
question the reliable bioavailability. 
4. Plasma concentrations do not correlate to estimated pain scores. Plasma concentrations are 
probably not a good estimate of analgesia. 
5. For further clarification, pharmacokinetic studies comparing SC or OTM administration of 
buprenorphine with IM or IV administration are needed. As well as more dose-effect studies 
of buprenorphine given to rabbits and different formulations of OTM buprenorphine to 
improve the bioavailability. 
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